JLP2 Antibody

What is the JLP2/JP-2 antibody and what protein does it target?

JLP2/JP-2 antibody targets Junctophilin-2 (JPH2), a critical membrane-binding protein that forms structural bridges between the plasma membrane and sarcoplasmic reticulum in cardiac and skeletal muscle cells . This protein plays an essential role in maintaining the 12-15 nm gap between sarcolemma and sarcoplasmic reticulum membranes in cardiac dyads . JPH2 is particularly important for normal excitation-contraction coupling in cardiomyocytes and contributes significantly to proper intracellular Ca²⁺ signaling via its involvement in ryanodine receptor-mediated calcium ion release .

Commercial JP-2 antibodies, such as rabbit polyclonal antibodies like ab110056, are typically developed using synthetic peptides corresponding to human JPH2 sequences . These antibodies recognize both the full-length JPH2 protein (predicted band size of approximately 74 kDa) and potentially its cleaved fragments that have distinct functional properties.

What applications can JP-2 antibody be used for in research settings?

JP-2 antibodies have been validated for multiple experimental applications including:

• Western Blotting (WB): Detects JP-2 protein in tissue lysates with recommended concentrations between 1-2 μg/mL . This application is particularly useful for quantifying total JPH2 expression levels and identifying cleaved fragments.

• Immunohistochemistry on Paraffin-embedded sections (IHC-P): Typically used at concentrations around 5 μg/ml for detecting JP-2 in formalin-fixed, paraffin-embedded tissues . This application allows visualization of JPH2 localization within tissue architecture.

• Protein-protein interaction studies: Although not explicitly mentioned in the search results, JP-2 antibodies may be employed in co-immunoprecipitation experiments to study interactions with calcium channels and other components of the excitation-contraction coupling machinery.

Each application requires specific optimization parameters depending on tissue type, fixation methods, and experimental objectives.

What species reactivity has been confirmed for commercially available JP-2 antibodies?

Commercial JP-2 antibodies have demonstrated reactivity with specific species, which is crucial to consider when designing experiments. For instance, the rabbit polyclonal JP-2 antibody (ab110056) has been confirmed to react with:

• Human samples: Successfully tested in human heart and skeletal muscle tissues using IHC-P applications .

• Mouse samples: Validated in mouse brain tissue lysates using Western blot applications, showing the expected band at approximately 74 kDa .

When considering antibodies for cross-species applications, researchers should verify whether the specific antibody has been validated for their species of interest. Some antibodies may work in additional species based on sequence homology, but this requires empirical validation. The manufacturer's product information typically indicates whether an application in a specific species is covered by their product guarantee .

How should I optimize JP-2 antibody concentration for Western blot analysis?

Optimizing JP-2 antibody concentration for Western blot analysis requires a systematic approach:

• Initial concentration testing: Begin with the manufacturer's recommended concentration range. For example, ab110056 has been successfully used at 1-2 μg/mL for Western blotting of mouse brain tissue lysates .

• Titration approach: Prepare a concentration gradient (e.g., 0.5, 1, 2, and 5 μg/mL) to determine the optimal antibody dilution that provides the best signal-to-noise ratio.

• Sample loading considerations: Optimize protein loading amounts (typically 20-50 μg total protein per lane) to ensure detection of JP-2 at its predicted molecular weight of 74 kDa .

• Exposure time optimization: Test multiple exposure times to identify conditions that provide clear visualization of the target band without background or non-specific binding.

• Blocking optimization: Test different blocking reagents (5% non-fat dry milk vs. 3-5% BSA) to minimize background while maintaining specific signal.

• Secondary antibody dilution: Adjust secondary antibody concentration in parallel with primary antibody optimization to maintain appropriate signal ratios.

Record all optimization parameters systematically to ensure reproducibility across experiments and researchers.

What sample preparation protocols are recommended for detecting JP-2 in cardiac tissue?

Effective sample preparation is crucial for successful JP-2 detection in cardiac tissue:

For Western blot analysis:

• Tissue homogenization: Rapidly homogenize fresh or flash-frozen cardiac tissue in ice-cold RIPA buffer supplemented with protease inhibitors to prevent protein degradation.

• Membrane fraction enrichment: Consider differential centrifugation to enrich membrane fractions, as JP-2 is primarily associated with membrane structures .

• Protein quantification: Use a reliable method (BCA or Bradford assay) to ensure equal loading across samples.

• Denaturation conditions: Heat samples at 95°C for 5 minutes in Laemmli buffer with reducing agent, but test milder denaturation conditions (70°C for 10 minutes) if membrane protein aggregation is observed.

• Gel selection: Use 8-10% SDS-PAGE gels for optimal resolution of the 74 kDa JP-2 protein .

For immunohistochemistry:

• Fixation: Use 10% neutral-buffered formalin for tissue fixation to preserve protein antigenicity and tissue architecture.

• Sectioning: Prepare 4-6 μm thick paraffin sections for optimal antibody penetration.

• Antigen retrieval: Perform heat-induced epitope retrieval using citrate buffer (pH 6.0) to expose antigenic sites that may be masked during fixation.

• Controls: Include positive control tissues (human heart or skeletal muscle) where JP-2 expression has been confirmed .

• Detection system: Use appropriate detection systems compatible with rabbit primary antibodies, such as HRP-polymer conjugated secondary antibodies.

What controls should I include when using JP-2 antibody for immunohistochemistry?

Rigorous experimental controls are essential for reliable immunohistochemistry results with JP-2 antibody:

• Positive tissue controls:

  • Include human heart tissue sections, which have been validated for JP-2 detection

  • Human skeletal muscle sections can serve as an alternative positive control

• Negative controls:

  • Primary antibody omission: Process tissue sections identically but omit the primary JP-2 antibody

  • Isotype control: Use a non-specific rabbit IgG at the same concentration as the JP-2 antibody

  • Absorption control: Pre-incubate JP-2 antibody with excess immunizing peptide to confirm binding specificity

• Internal controls:

  • Examine expected subcellular localization patterns (membrane-association at dyad junctions)

  • Verify expression in known positive cell types (cardiomyocytes) versus negative cell populations

• Cross-validation controls:

  • Compare staining patterns with alternative JP-2 antibodies from different suppliers or clones

  • Correlate immunohistochemistry findings with Western blot results from the same tissue samples

• Technical controls:

  • Include a dilution series of primary antibody (2.5, 5, and 10 μg/ml) to determine optimal concentration

  • Test multiple antigen retrieval methods to ensure optimal epitope exposure

Systematic documentation of all control results is crucial for publication and troubleshooting purposes.

How can JP-2 antibody be utilized to study calcium signaling in cardiomyocytes?

JP-2 antibody offers valuable insights into calcium signaling mechanisms through several advanced applications:

• Co-localization studies:

  • Combine JP-2 antibody with antibodies against calcium handling proteins (ryanodine receptors, SERCA, L-type calcium channels) in immunofluorescence microscopy

  • Quantify co-localization coefficients to assess dyadic junction integrity

  • Measure the 12-15 nm gap between sarcolemma and sarcoplasmic reticulum membranes using super-resolution microscopy techniques

• Structure-function correlation:

  • Correlate JP-2 localization with calcium spark frequency using concurrent immunostaining and calcium imaging

  • Assess JP-2 distribution in relation to T-tubule organization in healthy versus diseased cardiomyocytes

  • Evaluate spatial relationships between JP-2 and calcium handling proteins at nanoscale resolution

• Dynamic regulation studies:

  • Monitor JP-2 expression and localization changes during physiological and pathological stresses

  • Assess calcium transient parameters in relation to JP-2 distribution using combined immunocytochemistry and calcium imaging

  • Examine the impact of JP-2 cleavage on calcium handling by correlating N-terminal fragment generation with altered calcium signaling patterns

• Interventional approaches:

  • Use JP-2 antibody to measure protein levels after genetic manipulation (overexpression, knockdown)

  • Quantify JP-2 expression changes following pharmacological interventions targeting calcium handling

  • Correlate therapeutic interventions in heart failure models with JP-2 restoration and functional calcium signaling improvements

These approaches can be integrated with electrophysiological measurements, calcium imaging, and contractility assessments for comprehensive mechanistic insights.

What strategies can differentiate between full-length JPH2 and its cleaved N-terminal fragment?

Distinguishing between full-length JPH2 and its cleaved N-terminal fragment requires tailored experimental approaches:

• Western blot analysis optimization:

  • Utilize gradient gels (4-20%) to achieve optimal separation between the 74 kDa full-length protein and smaller N-terminal fragments

  • Select antibodies with known epitope locations (N-terminal vs. C-terminal specific) to differentiate fragments

  • Implement membrane fractionation protocols to separate membrane-bound full-length JPH2 from nuclear-translocated N-terminal fragments

• Subcellular localization assessment:

  • Perform nuclear extraction to specifically detect the N-terminal fragment that translocates to the nucleus following stress-induced cleavage

  • Use confocal microscopy with antibodies recognizing different JPH2 domains to visualize distinct subcellular locations

  • Quantify nuclear-to-cytoplasmic ratios of JP-2 immunoreactivity as an indicator of N-terminal fragment generation

• Functional studies:

  • Combine chromatin immunoprecipitation (ChIP) with JP-2 N-terminal-specific antibodies to identify DNA binding sites

  • Assess transcriptional repressor activity by measuring expression of target genes involved in cardiac stress responses

  • Correlate N-terminal fragment abundance with expression changes in genes implicated in cell growth, hypertrophy, inflammation, and fibrosis

• Calpain activity correlation:

  • Measure calpain activation in parallel with JP-2 cleavage product detection

  • Use calpain inhibitors to prevent N-terminal fragment generation and confirm fragment identity

  • Implement time-course experiments to track the sequence of calpain activation and JP-2 cleavage

These approaches provide comprehensive characterization of the dynamic regulation and distinct functions of JPH2 protein forms during cardiac physiology and pathology.

How can JP-2 antibody be utilized to investigate cardiac stress responses?

JP-2 antibody enables multifaceted investigation of cardiac stress responses:

• Stress-induced translocation monitoring:

  • Track the nuclear translocation of the N-terminal JP-2 fragment using fractionation followed by Western blot or immunofluorescence microscopy

  • Quantify the ratio of membrane-bound versus nuclear JP-2 immunoreactivity as a stress response indicator

  • Correlate nuclear accumulation with cardiac stress intensity and duration

• Transcriptional regulation assessment:

  • Identify genes regulated by the JP-2 N-terminal fragment using RNA-seq combined with JP-2 ChIP-seq

  • Measure expression changes in known JP-2-regulated genes involved in cell growth, differentiation, hypertrophy, inflammation, and fibrosis

  • Evaluate competition between JP-2 fragments and MEF2 transcription factors/TATA-binding proteins for DNA binding sites

• Cardioprotective mechanism investigation:

  • Assess JP-2 cleavage as a potential biomarker for early cardiac stress using sensitive detection methods

  • Evaluate the protective function of N-terminal fragment generation in attenuating pathological remodeling

  • Determine whether therapeutic interventions modify JP-2 cleavage patterns and subsequent transcriptional regulation

• Time-course analysis:

  • Map the temporal sequence of JP-2 cleavage, nuclear translocation, and transcriptional changes following stress induction

  • Correlate JP-2 fragment dynamics with functional recovery or deterioration in cardiac function

  • Establish temporal relationships between JP-2 cleavage and calcium handling disturbances

These approaches provide mechanistic insights into how JPH2 functions as a stress-responsive signaling molecule beyond its structural role at dyadic junctions.

What are common issues when using JP-2 antibody in Western blot and how can they be resolved?

Several technical challenges may arise when using JP-2 antibody in Western blotting:

• Multiple bands/non-specific binding:

  • Issue: Appearance of multiple bands beyond the expected 74 kDa band

  • Resolution: Increase blocking stringency (5% BSA instead of milk); optimize antibody concentration; include detergents in wash buffers; consider alternative antibody clone with higher specificity

• Weak or absent signal:

  • Issue: Insufficient JP-2 detection despite adequate loading controls

  • Resolution: Increase protein loading (up to 50 μg); optimize antibody concentration (try up to 2 μg/mL) ; extend primary antibody incubation time (overnight at 4°C); enhance ECL detection reagent sensitivity; ensure sample preparation preserves membrane proteins

• High background:

  • Issue: Non-specific background obscuring specific JP-2 signal

  • Resolution: Extend blocking time; increase wash frequency and duration; decrease secondary antibody concentration; prepare fresh buffers; use high-quality blocking reagents

• Inconsistent detection across experiments:

  • Issue: Variable JP-2 detection in repeated experiments

  • Resolution: Standardize tissue collection and processing; prepare larger batches of antibody dilutions; implement consistent loading controls; maintain consistent transfer conditions; document all experimental parameters

• Fragment detection challenges:

  • Issue: Difficulty distinguishing cleaved fragments from non-specific bands

  • Resolution: Include positive controls with known cleavage patterns; use gradient gels for better separation; compare N-terminal and C-terminal targeting antibodies; perform subcellular fractionation to enrich for specific fragments

A systematic approach to optimization, focusing on one variable at a time, will help identify and resolve specific issues affecting JP-2 antibody performance.

How should researchers interpret conflicting results with JP-2 antibody across different experimental methods?

Conflicting results across different experimental methods require systematic interpretation and validation:

• Method-specific limitations assessment:

  • Evaluate whether discrepancies reflect genuine biological differences or technical limitations

  • Consider that Western blot quantifies total protein levels while IHC reveals spatial distribution patterns

  • Recognize that native protein conformation in IHC versus denatured state in Western blot may affect epitope accessibility

• Experimental validation approaches:

  • Confirm antibody specificity through knockout/knockdown controls in each experimental system

  • Validate findings using alternative antibody clones recognizing different epitopes

  • Implement orthogonal detection methods (mass spectrometry, proximity ligation assay) to confirm observations

• Cross-methodological reconciliation:

  • Use subcellular fractionation to resolve discrepancies between total expression and localized signals

  • Employ multiple fixation and permeabilization protocols to address potential epitope masking in IHC

  • Normalize quantification methods appropriately for each technique

• Biological variation considerations:

  • Assess whether discrepancies reflect genuine biological heterogeneity in JP-2 expression or localization

  • Consider developmental, stress-induced, or disease-related alterations in JP-2 processing or localization

  • Document experimental conditions that might influence JP-2 status (calcium levels, oxidative stress, tissue preservation time)

• Data integration framework:

  • Develop a model that incorporates findings from multiple methodologies

  • Weight evidence based on technical rigor and biological relevance

  • Acknowledge limitations transparently in publications and presentations

This comprehensive approach enables researchers to distinguish technical artifacts from biologically meaningful observations.

What quantification methods are most appropriate for JP-2 expression studies?

Selecting appropriate quantification methods is crucial for reliable JP-2 expression analysis:

Best practices for JP-2 quantification include:

• Always include multiple biological and technical replicates (minimum n=3)

• Perform parallel analysis of full-length JPH2 and its cleaved fragments when studying stress responses

• Correlate protein expression with functional parameters (calcium handling, contractility)

• Implement blinded quantification to eliminate observer bias

• Verify linearity of detection methods within the experimental range

• Report both normalized and raw quantification data when possible

These approaches ensure robust and reproducible quantification of JP-2 expression in research settings.